Depression: meeting study criteria for depression at end of · people with stroke
It is very uncertain whether pharmacological interventions (antidepressants) changes depression: meeting study criteria for depression at end treatment… compared with placebo (very low certainty).
1 finding from 1 review
Scoring above cut‐off points for a depressive disorder at end of treatment (Analysis 1.2) · people with stroke
1 finding from 1 review
Depression: mean scores at end of treatment (Analysis 1.4) · people with stroke
1 finding from 1 review
Cognition at end of treatment · people with stroke
1 finding from 1 review
Activities of daily living · people with stroke
1 finding from 1 review
Disability: mean scores at end of treatment (Analysis 1.10) · people with stroke
1 finding from 1 review
Adverse events: death ‐ at end of treatment (Analysis 1.14) · people with stroke
It is very uncertain whether pharmacological interventions (antidepressants) changes adverse events: death ‐ at end of treatment Analysis 1.12 compared with placebo (very low certainty).
1 finding from 1 review
Severity of depression continuous measures ‐ HDRS total score at the end of the treatment · patients with depression during opioid agonist treatment for opioid dependence
1 finding from 1 review
Severity of depression continuous measures ‐ HDRS total score at the end of the treatment · patients with depression during opioid agonist treatment for opioid dependence
1 finding from 1 review
Acceptability ‐ total dropouts · women of any age, with PND up to 12 months
It is very uncertain whether antidepressants changes treatment acceptability ‐dropouts compared with any other pharmacological intervention (very low certainty).
1 finding from 1 review
RR 1.74 [0.99, 3.06]
Studies not reported
Very low
Suicide‐related outcomes Timing of outcome assessment: end of treatment (6 to 12 weeks treatment duration) · patients with borderline personality disorder
1 finding from 1 review
Psychosocial functioning Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Interpersonal problems Timing of outcome assessment: end of treatment (32 days to 24 weeks) · patients with borderline personality disorder
1 finding from 1 review
Attrition Timing of outcome assessment: end of treatment · patients with borderline personality disorder
Antidepressants may leads to higher attrition Timing of outcome assessment: end of treatment (5 weeks to… compared with placebo (low certainty).
1 finding from 1 review
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
BPD symptom severity Measured by: clinicians and self‐rated Timing of outcome assessment: end of treatment · patients with borderline personality disorder
1 finding from 1 review
Severity/intensity of MUPS (post‐treatment score on self report scales) Different self report and clinician‐rated scales (SOMS‐7, SCL‐90 Somatisation Score) · somatoform disorders in adults
1 finding from 1 review
Anxiety · somatoform disorders in adults
1 finding from 1 review
Depression (post‐treatment score on self report and clinician‐rated scales) Different self report and clinician‐rated scales (HDRS, BDI) · somatoform disorders in adults
1 finding from 1 review
Treatment response (post‐treatment score on self report and clinician‐rated scales) · somatoform disorders in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found